- •We investigated spin in RCTs with nonsignificant primary analyses.
- •Authors and editors should prioritize transparent reporting of RCTs.
- •Transparent reporting includes unbiased interpretation and recognizing limitations.
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Selective reporting in clinical trials: Analysis of trial protocols accepted by The Lancet.Lancet. 2008; 372: 201
- Discordance between conclusions stated in the abstract and conclusions in the article: Analysis of published randomized controlled trials of systemic therapy in lung cancer.J Clin Oncol. 2012; 30: 3552-3557
- Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes.J Am Med Assoc. 2010; 303: 2058-2064
- On the more insidious manifestations of bias in scientific reporting.J Am Coll Radiol. 2010; 7: 490-494
- Identifying outcome reporting bias in randomised trials on PubMed: Review of publications and survey of authors.BMJ. 2005; 330: 753
- Empirical evidence for selective reporting of outcomes in randomized trials: Comparison of protocols to published articles.JAMA. 2004; 291: 2457-2465
- Secondary endpoints can be validly analyzed, even if the primary endpoint does not provide clear statistical significance.Control Clin Trials. 1997; 18: 557-560
- Interventional management of neuropathic pain: NeuPSIG recommendations.Pain. 2013; 154: 2249-2261
- Clinical trials: Discerning hype from substance.Ann Intern Med. 2010; 153: 400-406
- “Spin” in scientific writing: Scientific mischief and legal jeopardy.Med Law. 2007; 26: 511-525
- Reporting of missing data and methods used to accommodate them in recent analgesic clinical trials: ACTTION systematic review and recommendations.Pain. 2014; 155: 1871-1877
- Reporting of primary analyses and multiplicity adjustment in recent analgesic clinical trials: ACTTION systematic review and recommendations.Pain. 2014; 155: 461-466
- Why most published research findings are false.PLoS Med. 2005; 2: e124
- Quality of reporting of randomized controlled trials published in Intensive Care Medicine from 2001 to 2010.Intensive Care Med. 2013; 39: 1386-1395
- Industry sponsorship and research outcome.Cochrane Database Syst Rev. 2012; 12: MR000033
- Research ethics: Ethical issues of data reporting and the quest for authenticity.Acad Emerg Med. 2000; 7: 691-694
- Comparison of registered and published primary outcomes in randomized controlled trials.JAMA. 2009; 302: 977-984
- CONSORT 2010 explanation and elaboration: Updated guidelines for reporting parallel group randomized trials.J Clin Epidemiol. 2010; 63: e1-e37
- Preferred Reporting Items for Systematic reviews and Meta-Analyses: The PRISMA Statement.BMJ. 2009; 339: b2535
- Secondary endpoints cannot be validly analyzed if the primary endpoint does not demonstrate clear statistical significance.Cont Clin Trials. 1997; 18: 550-556
- Discrepancies between registered and published primary outcome specifications in analgesic trials: ACTTION systematic review and recommendations.Pain. 2013; 154: 2769-2774
- The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: Systematic review.BMJ. 2011; 342: d1569
- Selective publishing of antidepressant trials and its influence on apparent efficacy.N Engl J Med. 2008; 358: 252-260
- Outcome reporting in industry-sponsored trials of gabapentin for off-label use.N Engl J Med. 2009; 361: 1963-1971
- Bias in reporting of end points of efficacy and toxicity in randomized, clinical trials for women with breast cancer.Ann Oncol. 2013; 24: 1238-1244
- Consistency in the analysis and reporting of primary end points in oncology randomized controlled trials from registration to publication: A systematic review.J Clin Oncol. 2012; 30: 210-216
The work was performed at the University of Rochester, Rochester, New York.
The manuscript was reviewed and approved by the Executive Committee of the ACTTION public-private partnership with the United States Food and Drug Administration.
The views expressed in this article are those of the authors and no official endorsement by the Food and Drug Administration (FDA) or the pharmaceutical companies that provided unrestricted grants to support the activities of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership should be inferred. Financial support for this project was provided by the ACTTION public-private partnership, which has received research contracts, grants, or other revenue from the FDA (U01 FD004187), Annovation, Astellas, Collegium, Depomed, Jazz, Johnson & Johnson, Lilly, Olatec, Pfizer, Purdue, Spinifex, and Teva. None of the authors have financial disclosures that are relevant to this article.